Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Iontophoretically applied corticosteroids
Outcome not reported · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Admission to hospital or death · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Resolution of symptoms · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review
Time to symptom resolution · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in symptom resolution: duration to symptoms resolved compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Serious adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Infections · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in infections compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
Congenital abnormality · pregnant women
Potent/very potent topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.56
9342 participants
Low
Orofacial cleft · pregnant women
Potent/very potent topical corticosteroids may leads to higher orofacial cleft compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.5
36348 participants
Low
Low birthweight · pregnant women
Potent/very potent topical corticosteroids may leads to higher low birth weight compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.58
47651 participants
Low
Preterm birth · pregnant women
Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.05
47651 participants
Low
Foetal death · pregnant women
Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.14
37086 participants
Low
Low Apgar score · pregnant women
Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.03
7514 participants
Low
Perinatal mortality · infants born of women at risk of preterm birth
Neonatal and child outcomes: corticosteroids leads to lower perinatal death (composite of fetal death (in utero death) and… compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.85 [0.77, 0.93]
Studies not reported
High
Neonatal death (baby born alive at any gestation and dies within 28 days) · infants born of women at risk of preterm birth
Neonatal and child outcomes: corticosteroids leads to lower neonatal death (infants born with signs of life who die within the… compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.78 [0.7, 0.87]
Studies not reported
High
Respiratory distress syndrome · infants born of women at risk of preterm birth
Neonatal and child outcomes: corticosteroids leads to lower respiratory distress syndrome№ of participants: 11,183(26 RCTs) compared with placebo or no treatment (high certainty).
1 finding from 1 review
RR 0.71 [0.65, 0.78]
Studies not reported
High
Intraventricular haemorrhage · infants born of women at risk of preterm birth
Neonatal and child outcomes: corticosteroids probably leads to lower intraventricular haemorrhage (IVH)№ of participants: 8475(12 RCTs) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
RR 0.58 [0.45, 0.75]
Studies not reported
Moderate